|1.||Minn, Heikki: 5 articles (01/2014 - 12/2002)|
|2.||Eskola, Olli: 5 articles (01/2014 - 12/2002)|
|3.||Lehtiö, Kaisa: 4 articles (01/2014 - 12/2002)|
|4.||Solin, O: 3 articles (01/2008 - 09/2001)|
|5.||Lehtiö, K: 3 articles (01/2008 - 09/2001)|
|6.||Eskola, O: 3 articles (01/2008 - 09/2001)|
|7.||Minn, H: 3 articles (01/2008 - 09/2001)|
|8.||Oikonen, Vesa: 3 articles (07/2004 - 12/2002)|
|9.||Grönroos, Tove: 3 articles (07/2004 - 01/2003)|
|10.||Solin, Olof: 2 articles (01/2014 - 04/2004)|
07/15/2004 - "The use of [(18)F]FETNIM for assessment of radiobiologic hypoxia requires a study with greater statistical power. "
01/01/2003 - "The distribution volume determined from dynamic PET study was compared with simple tumour to plasma and tumour to muscle ratios at 90-120 min. In skeletal muscle having a low but variable blood flow [2-6 ml/(100 gxmin)], differences in hypoxia-specific uptake of [(18)F]FETNIM remain small and may be hard to detect with PET. "
01/01/2008 - "We review here our experiences with two hypoxia-avid agents [(18)F]fluoroerythronitromidazole (FETNIM) and [(18)F] 2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)-acetamide (EF5) and focus on the similarities and differences of these two tracers in comparison to other radiolabeled 2-nitroimidazoles. "
01/01/2003 - "The increased hypoxia-specific retention of [(18)F]FETNIM in tissues with high blood flow, such as malignant tumours, may facilitate application of [(18)F]FETNIM as a hypoxia marker in oncological patients. "
01/01/2003 - "A good estimate of tissue hypoxia is accomplished by measuring the tissue to plasma [(18)F]FETNIM activity ratio using only a few late time points. "
11/01/2001 - "[(18)F]FETNIM uptake in the tumor was correlated with that in neck muscles and arterial plasma and compared with the findings of other PET studies. "
10/01/1999 - "Autoradiographic studies revealed that FDG accumulated in viable tumor areas, whereas FETNIM accumulated in both viable and partially necrotic areas. "
01/01/2014 - "Uptake of [18F]FETNIM was measured as tumor-to-plasma ratio (T/P) and fractional hypoxic volume (FHV), and that of [18F]FDG as standardized uptake value (SUV) and the metabolically active tumor volume (TV). "
07/15/2004 - "The definition of the fractional hypoxic volume (FHV) in the tumor was determined by multiple voxel-wise measurements of the uptake of [(18)F]FETNIM in well-oxygenated tissues and tumor. "
11/01/2001 - "The relationship between [(18)F]FETNIM uptake and the blood flow of the tumor was less obvious on a pixel-by-pixel level. "
|3.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/01/2012 - "The purpose of this study was to evaluate hypoxia in esophageal squamous cell carcinoma (SCC) with (18)F-fluoroerythronitroimidazole positron emission tomography/computed tomography ((18)F-FETNIM PET/CT). "
01/01/2012 - "Measuring tumor hypoxia with ¹⁸F-FETNIM PET in esophageal squamous cell carcinoma: a pilot clinical study."
01/01/2014 - "The relationship between the uptake of [18F]fluoroerythronitroimidazole ([18F]FETNIM), blood flow ([15O]H2O) and 2-[18F]fluoro-2-deoxyglucose ([18F]FDG) and immunohistochemically determined biomarkers was evaluated in squamous-cell carcinomas of the head and neck (HNSCC). "
|4.||Sarcoma (Soft Tissue Sarcoma)
10/01/1999 - "The effect of tumor size on F-18-labeled fluorodeoxyglucose and fluoroerythronitroimidazole uptake in a murine sarcoma model."
10/01/1999 - "The purpose of this study was to evaluate the effect of tumor size on the uptake of 18F-fluorodeoxyglucose (FDG) and fluoroerythronitroimidazole (FETNIM) in a murine sarcoma model. "
|5.||Head and Neck Neoplasms (Head and Neck Cancer)
11/01/2001 - "Uptake of [(18)F]FETNIM in head and neck cancer is highly variable and seems to be governed by blood flow at least in the early phase of tissue accumulation. "
01/01/2003 - "Dynamic imaging data from ten patients with head and neck cancer undergoing [(18)F]FETNIM PET was used in simulations and model fits to assess hypoxia marker uptake under different levels of blood flow. "
11/01/2001 - "Imaging of blood flow and hypoxia in head and neck cancer: initial evaluation with [(15)O]H(2)O and [(18)F]fluoroerythronitroimidazole PET."
|4.||Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)
|5.||Biological Markers (Surrogate Marker)
|6.||Deoxyglucose (2 Deoxy D glucose)